Laurion Capital Management LP Invests $2.76 Million in Aldeyra Therapeutics, Inc (ALDX)

Laurion Capital Management LP purchased a new position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 200,000 shares of the biotechnology company’s stock, valued at approximately $2,760,000. Laurion Capital Management LP owned approximately 0.95% of Aldeyra Therapeutics at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Rhumbline Advisers bought a new stake in Aldeyra Therapeutics during the 2nd quarter worth approximately $113,000. Bank of New York Mellon Corp increased its holdings in Aldeyra Therapeutics by 139.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 49,842 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 29,051 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Aldeyra Therapeutics during the 2nd quarter worth approximately $1,335,000. Schwab Charles Investment Management Inc. bought a new stake in Aldeyra Therapeutics during the 2nd quarter worth approximately $237,000. Finally, Stanley Laman Group Ltd. increased its holdings in Aldeyra Therapeutics by 54.4% during the 2nd quarter. Stanley Laman Group Ltd. now owns 98,892 shares of the biotechnology company’s stock worth $786,000 after purchasing an additional 34,863 shares in the last quarter. 69.10% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have commented on the company. Cantor Fitzgerald set a $23.00 price objective on Aldeyra Therapeutics and gave the stock a “buy” rating in a report on Monday, August 27th. Canaccord Genuity reissued a “buy” rating and set a $27.00 price objective on shares of Aldeyra Therapeutics in a report on Friday, August 10th. Zacks Investment Research lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 14th. Stifel Nicolaus boosted their price objective on Aldeyra Therapeutics from $16.00 to $36.00 and gave the stock an “in-line” rating in a report on Wednesday, September 26th. They noted that the move was a valuation call. Finally, Janney Montgomery Scott boosted their price objective on Aldeyra Therapeutics to $28.00 and gave the stock a “positive” rating in a report on Thursday, September 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Aldeyra Therapeutics has a consensus rating of “Buy” and a consensus target price of $24.64.

ALDX stock opened at $9.23 on Friday. The company has a market capitalization of $258.51 million, a PE ratio of -6.59 and a beta of 0.81. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.82 and a quick ratio of 4.82. Aldeyra Therapeutics, Inc has a 12-month low of $6.20 and a 12-month high of $16.70.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Wednesday, November 14th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.05). Analysts anticipate that Aldeyra Therapeutics, Inc will post -1.83 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2018/12/08/laurion-capital-management-lp-invests-2-76-million-in-aldeyra-therapeutics-inc-aldx.html.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Further Reading: Buyback For Investors Defined

Want to see what other hedge funds are holding ALDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aldeyra Therapeutics, Inc (NASDAQ:ALDX).

Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply